Search

Displaying results 1631 - 1640 of 8468 in total
  1. Drug

    Lumacaftor

    go.drugbank.com/drugs/DB09280
    ApprovedInvestigational

    [A20301] When used in combination with [DB08820] as the fixed dose combination product Orkambi, lumacaftor is specific for the management of CF in patients with delta-F508 mutations as it acts as a protein-folding … Lumacaftor is a drug used in combination with [DB08820] as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older.

  2. Target

    Protein-arginine deiminase type-2

    go.drugbank.com/bio_entities/BE0002316
    TargetHumans

    Catalyzes the deimination of arginine residues of proteins

    Synonyms: PAD-H19
  3. Drug

    Pepsin

    go.drugbank.com/drugs/DB13198
    ApprovedWithdrawn

    Interestingly, it has been used as a marker for laryngopharyngeal reflux (LPR), which is a common illness of otolaryngology (ear, nose and throat specialist) visits [A32604]. … Many causes of pancreatic insufficiency require that enzyme replacement therapy is started, including cystic fibrosis, pancreatic cancer, acute and chronic pancreatitis, as well as pancreatic surgery [

  4. Drug

    Esculin

    go.drugbank.com/drugs/DB13155
    Approved

    Esculin is found in barley. Vitamin C2 is generally considered a bioflavanoid, related to vitamin P esculin is a glucoside that naturally occurs in the horse chestnut (Aesculus hippocastanum), California Buckeye (Aesculus californica) an...

  5. Drug

    Exenatide

    go.drugbank.com/drugs/DB01276
    ApprovedInvestigational

    Exenatide was given FDA approval on April 28, 2005[L6106]. It is available as immediate- and extended-release formulations. … [L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021.

  6. Drug

    Sevabertinib

    go.drugbank.com/drugs/DB21667
    ApprovedInvestigational

    [L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608] … [L54638] Sevabertinib functions as a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2), also exhibiting activity against epidermal growth factor receptor (EGFR).

  7. Drug

    Avobenzone

    go.drugbank.com/drugs/DB09495
    ApprovedInvestigational

    Avobenzone has the ability to absorb ultraviolet light over wider range of wavelengths. It is included in many commercially available sunscreens which are used as wide spectrum sunscreens. … Avobenzone has an absorption maximum of 357 nm. Sunscreens containing avobenzone is indicated for providing protection from the sun.

    Mixtures: CARROT SUN SPF30 PA Plus Plus, Lovely Me:ex Bb Cream SPF 20/pa++
  8. Target

    Probable UbiX-like flavin prenyltransferase

    go.drugbank.com/bio_entities/BE0003027
    TargetEnzymeEscherichia coli O157:H7

    Involved in the non-oxidative decarboxylation and detoxification of phenolic derivatives under both aerobic and anaerobic conditions (PubMed:15979273). Flavin prenyltransferase that catalyzes the synthesis of the prenylated FMN cofactor ...

    Synonyms: PAD
  9. Drug

    Isotretinoin

    go.drugbank.com/drugs/DB00982
    ApprovedInvestigational

    [Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. … [L6579] The first isotretinoin-containing product was FDA approved on 7 May 1982.[L6574]

  10. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    [A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor